Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Skin Neoplasms × reolysin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Skin Neoplasms 1 Melanoma 1

Interventions

fludarabine 3 Cyclophosphamide 3 pembrolizumab 2 smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordic 1 sargramostim 1 reolysin 1 poly ICLC 1 peginterferon alfa-2a 1 osimertinib 1 gusacitinib 1 fludarabine phosphate 1 eprenetapopt 1 dabrafenib 1 cobimetinib 1 cemiplimab 1 Vorinostat 1 Temozolomide 1 Radiotherapy 1 Radiation 1 Poly I-C 1 Nivolumab 1 Monatide (IMS 3015) 1 Methods 1 MAPRE1 protein, human 1 Ipilimumab 1 Interleukin-15 1 Interleukin-12 1 Histone Deacetylase Inhibitors 1 Granulocyte-Macrophage Colony-Stimulating Factor 1 Gefitinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03282188 2018-05-04

REO13 Melanoma With of Without GM-CSF

University of Leeds

Phase 1/2 Withdrawn

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡